Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed

Jazz Pharmaceuticals plc

2023-Q1 EPS reported $1.04 revenue$892,812,000

GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).
Total revenue $892.8M (+10% YoY); neuroscience $654.0M (+7%), oncology $228.9M (+16%).
Xywav net sales $277.8M (+49%), Epidiolex $188.9M (+20%), Rylaze $85.9M (+58%).
FY 2023 guidance affirmed: rev $3.675-3.875B; GAAP EPS $5.90-$7.90; non-GAAP adj. EPS $16.90-$17.85.
Pipeline: zanidatamab ASCO June 2, JZP150 PTSD Phase 2 top-line late 2023, suvecaltamide ET Phase 2b 1H24.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.